Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged violations of securities laws, specifically related to misleading statements about its drug candidates [1][4]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Biohaven made false and misleading statements regarding the regulatory prospects of its drug candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder [4]. - The class period for the lawsuit is defined as March 24, 2023, to May 14, 2025, during which investors are encouraged to participate if they suffered losses [2]. Group 2: Investor Information - Investors who purchased Biohaven's securities during the class period are urged to contact the Schall Law Firm before September 12, 2025, to discuss their rights [2][3]. - The class has not yet been certified, meaning that until certification occurs, affected investors are not represented by an attorney [3].

Core Viewpoint - DJS Law Group is investigating Centene Corporation for potential violations of securities laws following a significant drop in its stock price after the company withdrew its financial guidance for 2025, indicating earnings would fall short of expectations [1]. Investigation Details - The investigation centers on whether Centene made misleading statements or failed to disclose critical information to investors [1]. - Following the announcement, Centene's shares plummeted by 36.6% in morning trading on July 2, 2025 [1]. Company Background - Centene Corporation is identified as a managed-care giant, indicating its significant role in the healthcare sector [1].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its operations and profitability following the termination of its merger agreement with Amazon [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that iRobot made false and misleading statements to the market during the class period from January 29, 2024, to March 11, 2025 [2][4]. - Investors who suffered losses during this period are encouraged to contact the Schall Law Firm before September 5, 2025, to participate in the lawsuit [2][3]. Group 2: Company Operations - The complaint alleges that iRobot overstated the impact of its restructuring plan on its operations and indicated that the company was unlikely to maintain profitability as a standalone entity [4]. - The misleading public statements made by iRobot throughout the class period led to investor damages once the truth about the company's situation was revealed [4].

CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to the demand for Krispy Kreme products at McDonald's locations. Specifically, defendants failed to disclose that lower demand at McDonald's locations accounted for the declining average weekly sales per store; the partnership with McDonald's was not profitable thereby c ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DoubleVerify Holdings, Inc. ("DoubleVerify Holdings, Inc." or the "Company") (NYSE: DV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DoubleVerify Holdings, Inc. investors who were adversely affected by alleged securities fraud between November 10, 2023 and February 27, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

The investigation concerns whether Caleres and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. ("Caleres" or the "Company") (NYSE: CAL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. CONTACT: Danielle Peyto ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. ("BellRing" or the "Company") (NYSE: BRBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether BellRing and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On this news, BellRing's stock price fell $14.88 per share, or 18.97%, t ...

[Click here for information about joining the class action] On June 30, 2025, Unicycive release issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." The press release stated that "[a]fter submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicyc ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, A ...